Good afternoon and thank you for joining us on today's call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded today, May 20, 2019. I would now like to turn the conference call over to Scott Youngstrom, CFO of ReShape Lifesciences. Please go ahead.

Good afternoon and thank you for joining us on today's call. I'm pleased to be joined by Bart Bandy, our new Chief Executive Officer, who will provide an overview of the Company's recent activities and business highlights. I will then review our financial results for the first quarter of 2019 and then turn the call back over to Bart to wrap up the call. As a reminder, this conference call as well as ReShape Lifesciences' SEC filings and website at www.reshapelifesciences.com including the Investor Information section of the website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those discussed due to the known and unknown risks, uncertainties and other factors. These and additional risks and uncertainties, are described more fully in the Company's filings with the Securities and Exchange Commission, including those factors identified as Risk Factors in our annual report on Form 10-K that was filed on May 16, 2019, and in our quarterly report on Form 10-Q that will be filed at later today May 20, 2019. As an additional reminder, our stock is listed OTC trading under the ticker RSLS. I will now turn the call over to our CEO, Bart Bandy. Bart?

Thanks, Scott. Good afternoon everyone, and thank you for dialing in to our call today. I'm pleased to be hosting my first call as CEO of ReShape Lifesciences. On today's call, I will start with a brief summary of the ReShape Lifesciences' growth opportunity and provide some of our recent operational and strategic highlights as well as our vision as we move forward. Scott will then provide an overview of our financial results and then I will wrap things up. Since joining the Company just over a month ago, I'm even more encouraged by the opportunity at ReShape Lifesciences. We have some work to do, both refining our corporate roadmap as well as further advancing our commercial strategy. And I look forward to updating you on our strategic initiatives and plan as well as our financial expectations as we move forward together. In the meantime, our value proposition is very much intact and we are making progress in providing increased access to our technologies as a standard of care for patients battling obesity. Personally, I've spent the majority of my career working in the obesity space, with over 10 years dedicated to launching and developing markets around the globe for LAP-BAND technology. The LAP-BAND itself has several life cycles, and I'm very happy that it has ended up at ReShape, and then I have the opportunity once again to lead the market development around this exciting and effective product, which remains the only approved weight loss implantable device, that is currently reimbursed in the United States. As you might remember over the past several years while LAP-BAND was owned by Allergan and then Apollo Endosurgery, sales of the product [indiscernible] see downward trajectory. It is very important to note that Allergan and Apollo invested minimally in the marketing and infrastructure…

Thanks Bart. Moving to our financial results for the first quarter of 2019. For the three months ended March 31, 2019, we reported sales of $3.1 million as compared to revenues from continuing operations of $450,000 in the three months ended December 31, 2018, and compared to revenues from continuing operations of $139,000 for the three months ended March 31, 2018. Our revenue numbers reflect $2.6 million in U.S. shipments and $500,000 of product that was sold to Apollo to support the OUS LAP-BAND operation. As a reminder, as part of our transition services agreement, Apollo has continued to sell the LAP- BAND OUS at a transfer price until we have established our infrastructure in those markets. Apollo reported net revenues of LAP-BAND products to OUS customers of $1.7 million and we are working diligently to bring this opportunity in-house so that we can begin to recognize these global revenues. We estimate that total worldwide LAP-BAND revenues in Q1 2019 to be approximately $4.3 million. We reported gross profit of $2.2 million in the first quarter of 2019 compared to $372,000 in the three months ended December 31, 2018 and $79,000 for the three months ended March 31, 2018. The gross margins of 72% are right in line with our expectations, as we work through our integration plans to eventually bring on the OUS sales process in-house. We anticipate that our margins will improve as this integration takes place between now and the end of the year. Selling, general and administrative expenses for the quarter were $5.4 million as compared to $4.3 million for the fourth quarter of 2018 and compared to $6.3 million for the first quarter of 2018. Included in SG&A expenses this quarter were $1.7 million of non-cash items related to stock-based compensation, amortization and depreciation. We…

Thanks, Scott. I cannot be more pleased to be at ReShape Lifesciences. As I mentioned earlier, I've spent the past 25 years in various operational and commercial leadership roles within the obesity space, with the bulk of my career spent with the LAP-BAND. Given my experience in building and growing organizations, products and sales obesity in laparoscopic markets in general and with LAP-BAND specifically, I feel like this is a great fit. In the short time, I've been at ReShape, I'm very encouraged to have already started a productive dialogue with many bariatric surgeons and the broader obesity community around the globe. I saw unique opportunity in ReShape and that there is truly a growing awareness of obesity, and there is a jewel of a technology that has been sidelined in the LAP-BAND. There is a real data on the market and it's been confirmed, there's an unmet need for a safe, effective and anatomy sparing solution for weight loss. We have an opportunity to rebuild this market from the ground up with a well known product that has solid long-term data demonstrating these capabilities, and I cannot be more excited to help bring the LAP-BAND back to doctors and patients around the globe. I look forward to spending more time with all of our stakeholders over the upcoming months and providing updates on all our strategies and processes. We thank our employees and investors for their support and look forward to sharing continued success with you in the future. Thank you again to everyone for joining the call today. End of Q&A: Ladies and gentlemen, thank you for your participation in today's conference. This does conclude today's program. You may all disconnect. Everyone have a wonderful day.